Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can AI-Powered MRI analysis outsmart prostate cancer?

NCT ID NCT06126172

Knowledge-focused Sponsor: Chang Gung Memorial Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looks at whether detailed analysis of MRI scans (called radiomics) can better predict how aggressive a prostate cancer is and whether it will come back soon after surgery. Researchers will study 125 men with prostate cancer who have an MRI before treatment. The goal is to improve risk assessment so that patients get the right level of treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Multiparametric magnetic resonance imaging (mpMRI) with radiomics analysis
What this could lead to
If successful, this could help doctors more accurately determine which prostate cancers are aggressive and need immediate treatment versus those that can be safely monitored.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly benefit participants. The results may not change current practice until confirmed in larger, more diverse groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 125 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2022

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged over 20 years old. 2. Suspected or confirmed prostate cancer. 3. Undergoing prostate mpMRI before clinical treatment. 4. Normal renal function(i.e.: estimated GFR ≧60). 5. No allergy history to gadolinium based contrast agent. 6. Agree to participate this study and sign informed consent. Exclusion Criteria: 1. mpMRI photography not completed. 2. mpMRI images are damaged or poor in quality and cannot be interpreted. 3. Without pathological examination confirmed prostate cancer. 4. Patient withdraw informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate cancer Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

Contacts and locations

Locations

  • Li-Jen Wang

    Taoyuan, Taiwan, 333, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.